SK287759B6 - Spôsob zvýšenia génovej expresie v transfektovaných bunkách s použitím acetyl L-karnitínu - Google Patents
Spôsob zvýšenia génovej expresie v transfektovaných bunkách s použitím acetyl L-karnitínu Download PDFInfo
- Publication number
- SK287759B6 SK287759B6 SK1187-2002A SK11872002A SK287759B6 SK 287759 B6 SK287759 B6 SK 287759B6 SK 11872002 A SK11872002 A SK 11872002A SK 287759 B6 SK287759 B6 SK 287759B6
- Authority
- SK
- Slovakia
- Prior art keywords
- alc
- gene
- dna
- cells
- carnitine
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 27
- 230000014509 gene expression Effects 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 9
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 24
- 238000001890 transfection Methods 0.000 description 16
- 108060001084 Luciferase Proteins 0.000 description 15
- 239000005089 Luciferase Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 239000002502 liposome Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- -1 alkanoyl L-carnitine Chemical compound 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000RM000077A IT1316990B1 (it) | 2000-02-17 | 2000-02-17 | Metodo per aumentare l'espressione genica per geni trasfettati. |
| PCT/IT2001/000057 WO2001061025A1 (en) | 2000-02-17 | 2001-02-09 | Method for increasing the gene expression of transfected genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK11872002A3 SK11872002A3 (sk) | 2002-11-06 |
| SK287759B6 true SK287759B6 (sk) | 2011-09-05 |
Family
ID=11454443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1187-2002A SK287759B6 (sk) | 2000-02-17 | 2001-02-09 | Spôsob zvýšenia génovej expresie v transfektovaných bunkách s použitím acetyl L-karnitínu |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030022859A1 (de) |
| EP (1) | EP1257658B1 (de) |
| JP (1) | JP4726378B2 (de) |
| KR (1) | KR100768264B1 (de) |
| AT (1) | ATE366320T1 (de) |
| AU (1) | AU2001237712A1 (de) |
| CA (1) | CA2400110A1 (de) |
| CY (1) | CY1106872T1 (de) |
| CZ (1) | CZ303403B6 (de) |
| DE (1) | DE60129206T2 (de) |
| DK (1) | DK1257658T3 (de) |
| ES (1) | ES2288164T3 (de) |
| HU (1) | HUP0204460A2 (de) |
| IT (1) | IT1316990B1 (de) |
| MX (1) | MXPA02007959A (de) |
| PL (1) | PL204125B1 (de) |
| PT (1) | PT1257658E (de) |
| SK (1) | SK287759B6 (de) |
| WO (1) | WO2001061025A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1316990B1 (it) * | 2000-02-17 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Metodo per aumentare l'espressione genica per geni trasfettati. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995000137A1 (de) * | 1993-06-21 | 1995-01-05 | Bernardini, Attilio | Verwendung von acylcarnitin zur behandlund von aids-krankheiten |
| EP0681839A3 (de) * | 1994-05-12 | 1997-11-12 | Hirohiko Kuratsune | Acylcarnitin-enthaltende pharmazeutische Zusammensetzung |
| US6040295A (en) * | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
| IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
| AU8765298A (en) | 1997-07-31 | 1999-02-22 | Larkom, L.L.C. | Shared high speed network access |
| IT1299172B1 (it) * | 1998-05-06 | 2000-02-29 | Sigma Tau Ind Farmaceuti | Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti |
| JP2002513775A (ja) * | 1998-05-06 | 2002-05-14 | トランジェーヌ、ソシエテ、アノニム | 細胞の中へのポリヌクレオチドのトランスフェクションを改良する治療組成物を調製するためのヌクレアーゼインヒビターまたはインターロイキン−１０（ｉｌ−１０）の使用、および遺伝子治療に有用な組成物 |
| WO2000001418A1 (en) * | 1998-07-02 | 2000-01-13 | Genzyme Corporation | Transgene expression in polarized cells |
| IT1316990B1 (it) * | 2000-02-17 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Metodo per aumentare l'espressione genica per geni trasfettati. |
-
2000
- 2000-02-17 IT IT2000RM000077A patent/IT1316990B1/it active
-
2001
- 2001-02-09 MX MXPA02007959A patent/MXPA02007959A/es active IP Right Grant
- 2001-02-09 DE DE60129206T patent/DE60129206T2/de not_active Expired - Lifetime
- 2001-02-09 AU AU2001237712A patent/AU2001237712A1/en not_active Abandoned
- 2001-02-09 EP EP01910129A patent/EP1257658B1/de not_active Expired - Lifetime
- 2001-02-09 JP JP2001559862A patent/JP4726378B2/ja not_active Expired - Fee Related
- 2001-02-09 ES ES01910129T patent/ES2288164T3/es not_active Expired - Lifetime
- 2001-02-09 US US10/203,924 patent/US20030022859A1/en not_active Abandoned
- 2001-02-09 PL PL365011A patent/PL204125B1/pl not_active IP Right Cessation
- 2001-02-09 KR KR1020027010503A patent/KR100768264B1/ko not_active Expired - Fee Related
- 2001-02-09 HU HU0204460A patent/HUP0204460A2/hu unknown
- 2001-02-09 CA CA002400110A patent/CA2400110A1/en not_active Abandoned
- 2001-02-09 SK SK1187-2002A patent/SK287759B6/sk not_active IP Right Cessation
- 2001-02-09 CZ CZ20022757A patent/CZ303403B6/cs not_active IP Right Cessation
- 2001-02-09 DK DK01910129T patent/DK1257658T3/da active
- 2001-02-09 WO PCT/IT2001/000057 patent/WO2001061025A1/en not_active Ceased
- 2001-02-09 PT PT01910129T patent/PT1257658E/pt unknown
- 2001-02-09 AT AT01910129T patent/ATE366320T1/de active
-
2004
- 2004-09-27 US US10/949,194 patent/US7560439B2/en not_active Expired - Fee Related
-
2007
- 2007-09-17 CY CY20071101195T patent/CY1106872T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1106872T1 (el) | 2012-09-26 |
| ITRM20000077A0 (it) | 2000-02-17 |
| IT1316990B1 (it) | 2003-05-26 |
| EP1257658B1 (de) | 2007-07-04 |
| US20050124570A1 (en) | 2005-06-09 |
| JP4726378B2 (ja) | 2011-07-20 |
| HUP0204460A2 (en) | 2003-04-28 |
| MXPA02007959A (es) | 2003-02-10 |
| KR20030072204A (ko) | 2003-09-13 |
| PL204125B1 (pl) | 2009-12-31 |
| CZ303403B6 (cs) | 2012-08-29 |
| US20030022859A1 (en) | 2003-01-30 |
| ES2288164T3 (es) | 2008-01-01 |
| SK11872002A3 (sk) | 2002-11-06 |
| ATE366320T1 (de) | 2007-07-15 |
| DE60129206T2 (de) | 2008-03-06 |
| PL365011A1 (en) | 2004-12-27 |
| DE60129206D1 (de) | 2007-08-16 |
| CZ20022757A3 (cs) | 2003-02-12 |
| PT1257658E (pt) | 2007-09-14 |
| KR100768264B1 (ko) | 2007-10-18 |
| AU2001237712A1 (en) | 2001-08-27 |
| WO2001061025A1 (en) | 2001-08-23 |
| EP1257658A1 (de) | 2002-11-20 |
| JP2003522544A (ja) | 2003-07-29 |
| US7560439B2 (en) | 2009-07-14 |
| CA2400110A1 (en) | 2001-08-23 |
| ITRM20000077A1 (it) | 2001-08-17 |
| DK1257658T3 (da) | 2007-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2583375C (en) | Regulation of oncogenes by micrornas | |
| US9040492B2 (en) | Double-stranded lipid-modified RNA having high RNA interference effect | |
| AU2011322114A1 (en) | Compositions and methods for activating expression by a specific endogenous miRNA | |
| TW200930811A (en) | Transfection reagent and method for enhancing transfection efficiency | |
| WO2009070609A2 (en) | Therapeutic targeting of il-6 using sirna in neutral liposomes | |
| US6020318A (en) | DNA methyltransferase genomic sequences and antisense oligonucleotides | |
| Phillips | Gene therapy for hypertension: sense and antisense strategies | |
| SK287759B6 (sk) | Spôsob zvýšenia génovej expresie v transfektovaných bunkách s použitím acetyl L-karnitínu | |
| CN116803424B (zh) | Slc17a5基因抑制剂及其用途 | |
| KR100930282B1 (ko) | ＮＩＫ 유전자에 대한 ｓｉＲＮＡ 및 이를 포함하는 간질환치료제 | |
| CN1221795A (zh) | 人白介素6核转录因子表达质粒系列及其在肿瘤治疗中的应用 | |
| KR100631488B1 (ko) | 단백질 도입부위 및 막활성화 부위가 함유된 새로운 합성펩타이드 및 이를 이용한 유전자 전달 방법 | |
| AU774116B2 (en) | Use of prohibitin RNA in treatment of cancer | |
| CN101328475B (zh) | 核酸分子nrn1sr1及其在制备抗癌药物中的应用 | |
| CN108578699A (zh) | 分子靶标在牙种植体修复中的应用 | |
| WO2014113431A2 (en) | Methods and compositions for targeting immunoglobulins | |
| Raemdonck et al. | 655. Intracellular Time-Controlled Delivery of siRNA from Cationic Nanogel Depots | |
| Cheikha-Douaihy | Factors affecting DNA uptake by mammalian cells | |
| US20060189560A1 (en) | Molecular method to augment RNA mediated gene silencing | |
| WO1999017807A1 (en) | Use of a vasoactive compound in the enhancement of gene delivery | |
| KR20150057139A (ko) | ｍｉＲＮＡ를 포함하는 방사선 민감성 증진용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20120209 |